DGAT1 and prostate carcinoma: Previous studies have shown that targeting DGAT1 in GBM or prostate cancer can impair FA metabolism and thus induce mitochondrial damage, excessive ROS production, and ultimately apoptosis [56] through a blockade of the autophagy flux [62].